Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information. Is the behavior connected to dementia, or was it ...

In early-stage Alzheimer's, changes in abilities or behavior may be minor and only noticeable to family and close friends. Some symptoms typify this stage.

Nearly half the Alzheimer's disease patients treated with TrueBinding's investigational therapy TB006 showed cognitive improvement signs.

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Moderate stage Alzheimer's is the second and longest stage of this brain disease, likely marked by increased forgetfulness, confusion, and trouble speaking.

Dietary supplementation with the amino acid L-serine may help reduce the memory loss associated with Alzheimer's disease.

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

Columnist Ray Burow clarifies some common misconceptions about Alzheimer's disease, particularly that it's a type of mental illness.

Read about a study finding a single, low-dose of methylene blue in healthy people boosted their short-term memory by activating relevant brain regions.

The FDA has approved BrainSee, a software for predicting Alzheimer's dementia in people with mild cognitive impairments.